Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents

Authors
Choe, Young JuneYi, SeonjuHwang, InsobKim, JiaPark, Young-JoonCho, EunheeJo, MyoungyounLee, HyunjuChoi, Eun Hwa
Issue Date
31-1월-2022
Publisher
ELSEVIER SCI LTD
Keywords
Coronavirus disease 2019; Covid-19; SARS-CoV-2; Vaccine; Vaccination; Adolescent
Citation
VACCINE, v.40, no.5, pp.691 - 694
Indexed
SCIE
SCOPUS
Journal Title
VACCINE
Volume
40
Number
5
Start Page
691
End Page
694
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/137519
DOI
10.1016/j.vaccine.2021.12.044
ISSN
0264-410X
Abstract
In South Korea, all 12th grade students (highs school seniors) were offered BNT162b2 vaccine starting July 19, 2021; while 10th-11th grade students were not eligible. We conducted a nationwide retrospective cohort study by to determine the safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents against SARS-CoV-2 infection. Among 444,313 persons who received the first dose of vaccine, reporting rate for myocarditis and/or pericarditis was 1.8 per 100,000 (95% C.I. 0.8-3.5) among first-dose recipients and 4.3 per 100,000 (95% C.I. 2.6-6.7) in second-dose recipients. Vaccine effectiveness against symptomatic/asymptomatic SARS-CoV-2 infection 14 days post-first dose vaccination was 91.1% (95% C.I. 89.6-92.5), and 14 days post-second dose was 99.1% (95% C.I. 98.5-99.5). In this retrospective cohort study, BNT162b2 vaccination was safe and was associated with a significantly lower risk of SARS-CoV2 infection, suggesting that vaccination in adolescent may reduce the burden of Covid-19. (c) 2021 Elsevier Ltd. All rights reserved.
Files in This Item
There are no files associated with this item.
Appears in
Collections
ETC > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE